webinar register page

The Cholesterol Wars: Navigating a Shifting Battlefield
Statin therapy is the recommended treatment for lowering low-density lipoprotein cholesterol (LDL-C) and reducing atherosclerotic cardiovascular disease (ASCVD) risk. However, evidence-based and guideline-recommended therapies, including ezetimibe and PCSK9 inhibitors, continue to be underutilized, even among the highest risk patients. Consequently, an unmitigated burden of cardiovascular risk persists. More education is urgently needed to address this problem. To that end, NATF invites you to join us for a virtual series of webinars that discuss some of these key issues in cholesterol management.

Covered topics include:

Week 1: Identifying Patients Who Would Benefit from PCSK9 Inhibitors

Week 2: The Critical Importance of Lowering LDL-C in High-Risk Patients

Week 3: Recent Cholesterol Guidelines and Integration into Clinical Practice

Week 4: Current Treatments for LDL Lowering — and Why Patient Access Is So Important
Sep 9, 2022 12:00 PM
Sep 16, 2022 12:00 PM
Sep 23, 2022 12:00 PM
Sep 30, 2022 12:00 PM
Time shows in
* Required information
Registration fee $25.00USD
Pay and Register Secured by